Status:
UNKNOWN
Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Load
Lead Sponsor:
Samsung Medical Center
Conditions:
Carcinoma, Hepatocellular
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Antiviral therapy for HBV may play an important role here, as a large observation study from Taiwan reported that the use of nucleos(t)ide analogues (NUC) was associated with 33% reduction in HCC recu...
Detailed Description
HCC is a major global health problem, which is the third leading cause of cancer-related deaths, and accounts for 7% of all cancers worldwide. Curative treatment, such as SR, RFA has improved patients...
Eligibility Criteria
Inclusion
- Hepatocellular carcinoma (clinically or histologically)
- chronic hepatitis B
- serum HBV DNA \< 2000 IU/mL
- HCC stage BCLC 0 or A
- treated or will be treated with RFA or surgical resection
Exclusion
- co-infected with HCV, HIV
- currently using antiviral drug (lamivudine, adefovir, clevudine, tenofovir, entecavir, telbivudine) or interferon
- other malignancy
- dialysis
- pregnancy
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2019
Estimated Enrollment :
124 Patients enrolled
Trial Details
Trial ID
NCT02308319
Start Date
January 1 2015
End Date
June 1 2019
Last Update
December 4 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.